3rd RAS/MAPK Pathway Targeted Drug Discovery Summit
Evvnt Promotion / evvnt
22.02.2022 - 24.02.2022 Online, USA
Time: 9:00 AM - 3:30 PM
Conference themes
For decades, RAS proteins have been considered “undruggable.” This all changed following the recent approval of the first-ever targeted KRAS G12C therapy, marking a major landmark for this community. This breakthrough has certainly laid out a roadmap for future success, with more investment and innovation in the field than ever before, particularly within emerging discovery strategies being pursued by the biopharma industry.
For decades, RAS proteins have been considered “undruggable.” This all changed following the recent approval of the first-ever targeted KRAS G12C therapy, marking a major landmark for this community. This breakthrough has certainly laid out a roadmap for future success, with more investment and innovation in the field than ever before, particularly within emerging discovery strategies being pursued by the biopharma industry.
Professional congress organizer (PCO)
Hanson Wade
Hanson Wade
Enquiries and Registration:
https://go.evvnt.com/913421-2?pid=4832
Ms. Georgina FitzGerald
General Medicine
Organizer contact info
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International promotes access to education and training for all regardless of social, geographic and national borders."
